ArticleFrontiers in oncology2026

Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event.

Kristin Mersmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.